← Back to Clinical Trials
Recruiting NCT05370014

NCT05370014 Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05370014
Status Recruiting
Phase
Sponsor University of South Carolina
Condition SARS- CoV-2
Study Type INTERVENTIONAL
Enrollment 500 participants
Start Date 2023-01-03
Primary Completion 2026-05-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 500 participants in total. It began in 2023-01-03 with a primary completion date of 2026-05-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study tests the efficacy of a dyadic intervention to mitigate the adverse health consequences of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2 )(COVID-19) in African American (AA) adults with pre-existing chronic health conditions and their informal carepartners (IC). Socioeconomically disadvantaged, older, and Black/African American from rural regions are burdened with greater rates of chronic diseases such as diabetes, hypertension, chronic kidney disease, cardiovascular disease, and stroke.

Eligibility Criteria

Inclusion Criteria: COVID-19 survivor inclusion criteria * African American * Male and female * Living in a Medically Underserved Area and/or a designated rural area of South Carolina * ≥ 18 years and above * A history of a COVID-19-associated hospitalization, ER or Urgent Care visit since March 11th, 2020 * A previous diagnosis of one or more of the following conditions: type 2 diabetes, hypertension, cardiovascular disease, chronic kidney disease, or stroke (\>3 months) -Carepartner inclusion criteria * Male and female * ≥ 18 years and above * Must live on the same property or community, preferably within a 40-mile radius of the survivor * Primarily responsible for care provision and/or care/social support in the home (i.e., is not paid for services) Exclusion Criteria: * Survivor and Carepartner exclusion criteria • Enrolled in related clinical trials

Contact & Investigator

Central Contact

Study PI

✉ magwoodg@sc.edu

📞 8037779160

Principal Investigator

Gayenell S Magwood, PhD

PRINCIPAL INVESTIGATOR

University of South Carolina

Frequently Asked Questions

Who can join the NCT05370014 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying SARS- CoV-2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05370014 currently recruiting?

Yes, NCT05370014 is actively recruiting participants. Contact the research team at magwoodg@sc.edu for enrollment information.

Where is the NCT05370014 trial being conducted?

This trial is being conducted at Columbia, United States.

Who is sponsoring the NCT05370014 clinical trial?

NCT05370014 is sponsored by University of South Carolina. The principal investigator is Gayenell S Magwood, PhD at University of South Carolina. The trial plans to enroll 500 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology